<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465749</url>
  </required_header>
  <id_info>
    <org_study_id>ZOC20150503</org_study_id>
    <nct_id>NCT02465749</nct_id>
  </id_info>
  <brief_title>Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa</brief_title>
  <official_title>Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Jeeyor Medical Research Co.,Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the role of continuous oxygen therapy combined
      with blue light deprivation in prevention and control of retinitis pigmentosa, in order to
      find a new strategy of treatment for retinitis pigmentosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinitis pigmentosa (RP) is one of of the major causes of blindness in ocular diseases.Up to
      now, the etiology of RP remained unclear, and there are no effective therapeutic methods.
      Several studies had showed that the retina of RP may be anoxic, and oxygen therapy, such as
      hyperbaric oxygen (hyperbaric oxygen, HBO) treatment, had shown a definite effect on RP. The
      investigators' previous researches also found that the retinal vessel oxygen saturation in
      patients with RP who were older than 40 years were significantly lower than normal controls,
      suggesting that oxygen may play an important role in the development of RP. Besides, many
      studies have revealed that blue light could damage retina pigment epithelium cells and
      photoreceptor cell specially. Therefore, investigators will combine continuous oxygen therapy
      and blue light deprivation therapy in the treatment for RP in this study, in order to find a
      new strategy of treatment for RP.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the percentage of patients preserved 80% of the initial visual acuity at 5 years follow-up.</measure>
    <time_frame>at 5 years follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ERG b-wave mean values</measure>
    <time_frame>at 5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of visual field</measure>
    <time_frame>at 5 years follow-up</time_frame>
    <description>visual field</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fundus changes of fluorescence fundus angiography</measure>
    <time_frame>at 5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal vessel oxygen saturation</measure>
    <time_frame>at 5 years follow-up</time_frame>
    <description>Retinal Oximetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intra-ocular pressure</measure>
    <time_frame>at 1, 2, 3, 4 and 5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>at 1, 2, 3, 4 and 5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Finger pulse oxygen saturation</measure>
    <time_frame>at 1, 2, 3, 4 and 5 years follow-up</time_frame>
    <description>Finger pulse oximetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the mutant genes of retinitis pigmentosa</measure>
    <time_frame>at admission</time_frame>
    <description>gene screening</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">404</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Continuous Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous oxygen intake and routine drug treatment .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blue Light Deprivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wearing blue light-absorbing sunglasses at daily time and routine drug treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous Oxygen Therapy Combined With Blue Light Deprivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous oxygen intake , Wearing blue light-absorbing sunglasses at daily time and routine drug treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Routine drug treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuous oxygen</intervention_name>
    <description>Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;</description>
    <arm_group_label>Continuous Oxygen</arm_group_label>
    <arm_group_label>Continuous Oxygen Therapy Combined With Blue Light Deprivation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>blue light-absorbing sunglasses</intervention_name>
    <description>Wearing blue light-absorbing sunglasses at daily time;</description>
    <arm_group_label>Blue Light Deprivation</arm_group_label>
    <arm_group_label>Continuous Oxygen Therapy Combined With Blue Light Deprivation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound thrombosis capsule sig: 1.5g/tid</intervention_name>
    <description>Compound thrombosis capsule sig: 1.5g/tid</description>
    <arm_group_label>Continuous Oxygen</arm_group_label>
    <arm_group_label>Blue Light Deprivation</arm_group_label>
    <arm_group_label>Continuous Oxygen Therapy Combined With Blue Light Deprivation</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginkgo biloba pills sig: 300mg/tid;</intervention_name>
    <description>Ginkgo biloba pills sig: 300mg/tid;</description>
    <arm_group_label>Continuous Oxygen</arm_group_label>
    <arm_group_label>Blue Light Deprivation</arm_group_label>
    <arm_group_label>Continuous Oxygen Therapy Combined With Blue Light Deprivation</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin B sig: 10mg/tid</intervention_name>
    <description>Vitamin B sig: 10mg/tid</description>
    <arm_group_label>Continuous Oxygen</arm_group_label>
    <arm_group_label>Blue Light Deprivation</arm_group_label>
    <arm_group_label>Continuous Oxygen Therapy Combined With Blue Light Deprivation</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin AD sig: 1 tablet/tid</intervention_name>
    <description>Vitamin AD sig: 1 tablet/tid</description>
    <arm_group_label>Continuous Oxygen</arm_group_label>
    <arm_group_label>Blue Light Deprivation</arm_group_label>
    <arm_group_label>Continuous Oxygen Therapy Combined With Blue Light Deprivation</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe patients with RP who meet the following criteria: (1) the EDTRS visual acuity
             of the good eye &lt; 0.3 (low vision);(2) the radius of central visual field&lt; 10 °(low
             vision)

          2. Age range from 18 to 60 years old, sex unlimited

          3. Able to adhere to treatment for more than 12 months

          4. Willing to participate in this trial, and sign the informed consent

        Exclusion Criteria:

          1. Serious opacity of cornea, lens or vitreous body which can't have clear fundus
             examination

          2. Patients with severe systemic diseases who was unable to tolerate the examinations,
             such as heart failure, respiratory failure, sepsis, severe anemia, kidney disease,
             history of eye surgery and so on

          3. Patients who was unable to tolerate oxygen treatment, such as severe pulmonary edema,
             deformity of the respiratory tract, respiratory tract infection, tuberculosis,
             patients with pregnancy, and so on
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qianying Gao, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qianying Gao, PHD</last_name>
    <phone>13751829105/18922103820</phone>
    <email>gaoqy@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qianying Qao, PHD</last_name>
      <phone>13751829105/18922103820</phone>
      <email>gaoqy@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>June 4, 2015</last_update_submitted>
  <last_update_submitted_qc>June 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Qianying Gao</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>oxygen</keyword>
  <keyword>blue light</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

